ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval
When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would perform better in a subgroup of patients with high folate receptor alpha (FRα) expression.
On Tuesday, researchers uncorked topline Phase III results suggesting it was right — and investors cheered on the news with a 40% boost to ImmunoGen’s stock price $IMGN. CEO Mark Enyedy says he’s going after an accelerated approval and plans to file in the first quarter of 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.